Cipher Pharmaceuticals Reports Adjusted EBITDA1 of $1.2 million in Q3 2016

Cipher Pharmaceuticals (NASDAQ:CPHR,TSX:CPH) announced its financial and operational results for Q3 2016.
As quoted in the press release:

Financial Highlights for Q3 2016
(all figures compared to Q3 2015, unless otherwise noted)

• Total revenue of $9.3 million, an increase of 10% from $8.5 million in Q3 2015.
• Licensing revenue of $6.8 million, an increase of 9% over $6.3 million in Q3 2015.
• Canadian product revenue of $1.0 million, up 67% from $0.6 million in Q3 2015.
• U.S. product revenue of $1.5 million, compared with $1.6 million in Q3 2015.
• Net loss of $21.8 million, or $0.81 per basic share, which includes a non-cash impairment charge on intangible assets of $17.3 million and on goodwill of $2.3 million related to the Company’s U.S. segment.
• Adjusted EBITDA1 of $1.2 million, compared with $1.9 million.
• Excluding the impairment charge, net loss would have been $2.2 million, or $0.08 per basic share.
• Net cash flow from operating activities of $2.0 million.
• $30.6 million in cash and cash equivalents at quarter end, up from $27.2 million at year end.

Click here for the full press release